Amgen, Novartis' migraine drug hits endpoint in PhII trial - FierceBiotech

FierceBiotech

Amgen, Novartis' migraine drug hits endpoint in PhII trial FierceBiotech Amgen ($AMGN) and Novartis' ($NVS) migraine drug erenumab has hit the primary endpoint in a Phase II trial. The mid-phase success raises the possibility that Amgen will for approval following the upcoming readout from a Phase III trial of the drug, ... In Race to Relief, Amgen Touts New But Incomplete Migraine DataXconomy Amgen says migraine prevention drug meets main goal of studyReuters Amgen (AMGN) Announces Erenumab Phase 2 Met Primary Endpoint in Chronic Migraine PreventionStreetInsider.com CNBC -Seeking Alpha -Financial Times -Pharmaceutical Business Review all 14 news articles »

from Health - Google News http://news.google.com/news/url?sa=t&fd=R&ct2=us&usg=AFQjCNFRLL1fgfKFA88Wc6Zi1uBO0QHCFg&clid=c3a7d30bb8a4878e06b80cf16b898331&cid=52779129658590&ei=GF1ZV_D3O8vO3gG1h7GYAQ&url=http://www.fiercebiotech.com/biotech/amgen-novartis-migraine-drug-hits-endpoint-phii-trial
via IFTTT